Business Context and Reporting Period
Company: Inter Parfums, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2006
Business Overview: Inter Parfums manufactures, markets, and distributes fragrances, cosmetics, and health and beauty aids. Operations are divided into two segments: European-based operations (prestige brands, primarily via 73% owned subsidiary Inter Parfums, S.A.) and United States-based operations (mass-market and specialty retail). Key brands include Burberry (59% of net sales), Lanvin, Paul Smith, and Gap/Banana Republic.
Key Financial Metrics
All figures in thousands, except per share data.
| Metric | Three Months Ended Sep 30, 2006 | Nine Months Ended Sep 30, 2006 |
|---|---|---|
| Net Sales | $89,690 | $230,876 |
| Gross Margin | $48,688 (54.3%) | $128,655 (55.7%) |
| Operating Income | $9,425 | $24,991 |
| Net Income | $4,645 | $12,257 |
| Diluted EPS | $0.23 | $0.60 |
| Cash & Equivalents | $40,683 (as of Sep 30, 2006) | |
| Short-term Investments | ||
| Total Current Assets | $247,660 | |
| Total Current Liabilities | $120,716 | |
| Working Capital | $126,944 | |
| Long-term Debt | $7,311 (excluding current portion) | |
| Operating Cash Flow (9mo) | $(6,554) (Used) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 19% ($14.2M) for the three months and 11% ($23.0M) for the nine months ended September 30, 2006, compared to the prior year.
- Europe: Sales up 13% (3mo) and 10% (9mo), driven by Lanvin Rumeur and Burberry London launches.
- United States: Sales surged 64% (3mo) and 20% (9mo), primarily due to new shipments to Gap, Gap Outlet, and Banana Republic stores.
- Profitability: Net income rose 24% ($0.9M) for the quarter and 8% ($0.9M) for the nine-month period. Operating margins remained steady at 11.0% for the nine-month period.
- Margins: Gross margin percentage declined slightly to 54% (3mo) and 56% (9mo) from 56% and 57% in the prior year, attributed to lower-margin US product mix and increased promotional activities.
- Cash Flow: Operating cash flow turned negative, using $6.6M for the nine months ended September 30, 2006, compared to providing $7.7M in the prior year. This was driven by a 40% increase in inventory and a 28% increase in accounts receivable to support new product launches and the holiday season.
Guidance, Outlook, and Material Events
- New Licenses:
- Van Cleef & Arpels: Signed an exclusive worldwide license in September 2006. Agreed to a €18 million ($22.5M) upfront royalty payment (recorded in accrued expenses) and purchase of ~$4.0M inventory. Effective January 1, 2007.
- Quiksilver/Roxy: Signed in March 2006. First product line (Roxy fragrance) expected late 2007.
- Gap/Banana Republic: Launched the "Banana Republic Discover Collection" in September 2006. A separate line for Gap stores is expected in early 2007. Start-up costs of ~$5.0M were incurred in the first nine months of 2006.
- Capital Expenditures: Expected to range between $3.5M and $4.5M for 2006 due to ambitious launch schedules and office renovations.
- Dividends: Quarterly cash dividend of $0.04 per share maintained. Next payment scheduled for January 15, 2007.
- Accounting Changes: Adopted SFAS 123(R) for share-based payments effective January 1, 2006, reducing net income by $0.34M for the nine-month period.
Investor Verification Checklist
- Van Cleef & Arpels Integration: Verify the timing and financial impact of the €18M upfront payment and the January 2007 inventory purchase.
- Gap/Banana Republic Margins: Monitor the profitability of the new US specialty retail lines, as margins on existing Gap product lines are currently minimal.
- Inventory Levels: Assess the risk of inventory obsolescence given the 40% increase in inventory levels to support new launches.
- Burberry Dependency: Note that Burberry represents 59% of net sales; review the impact of the amended royalty calculation method effective January 1, 2006.
- Foreign Exchange: Review the impact of currency fluctuations on European operations, as the company hedges but remains exposed to EUR/USD rates.